Tag: Sandoz

Novartis sells parts of its Sandoz US portfolio to Aurobindo Pharma

Novartis announced it has agreed to sell selected portions of its Sandoz US portfolio, specifically the Sandoz US dermatology business and generic US oral solids portfolio, to Aurobindo Pharma.

Sandoz obtained EC approval for infliximab biosimilar

Sandoz, a Novartis division and the global leader in biosimilars, announced that the European Commission (EC) has approved Zessly (infliximab) for use in Europe.

Sandoz and Pear Therapeutics will jointly develop digital therapeutics

digital drug
Sandoz, a Novartis division and global leader in generic pharmaceuticals and biosimilars, entered into a collaboration with Pear Therapeutics to commercialize and continued development of novel prescription digital therapeutics.

Tilray set up a strategic alliance with a leading Canadian pharma company

medicinal cannabis
Tilray, a licensed producer of medical cannabis, signed a binding letter of intent to be the collaborator of a major pharma company to accelerate innovation and increase availability of high quality medical cannabis products.

Sandoz and Biocon partnered to develop multiple biosimilars

Sandoz, a Novartis division, announced a global partnership with Asia's premier biopharmaceuticals company, Biocon, to develop, manufacture and commercialize multiple biosimilars

Sandoz obtained EU approval for Rixathon

Sandoz, a Novartis division, and the pioneer and global leader in biosimilars, announced today that the European Commission (EC) has approved Rixathon